Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)

NCT05446870 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

160

Enrollment

INDUSTRY

Sponsor class

Conditions

High-grade Serous Ovarian Carcinoma
Ovarian Carcinoma

Interventions

BIOLOGICAL: Pembrolizumab
DRUG: Paclitaxel
DRUG: Carboplatin
BIOLOGICAL: Avastin
BIOLOGICAL: MK-4830
DRUG: Docetaxel

Sponsor

Merck Sharp & Dohme LLC